Trial · NCT00071058
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
NCT00071058, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2012-09-12
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer. Trials, record NCT00071058. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00071058
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
- NCT number
- NCT00071058
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Adrenal Cortex Neoplasms
- Interventions
- XR9576 (Tariquidar)
- First posted
- 2003-10-10
- Last updated
- 2012-09-18
- Results first posted
- 2012-09-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With a Partial or Complete Response | Every 6 weeks for up to a year | Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response is defined as the disappearance of all signs and symptoms of tumor for a period of at least 4 weeks. Partial response is defined as at least a 30% decrease in the sum of the longest diameter of all measured lesions lasting for a period of 4 weeks. |
| Secondary | Number of Participants With Adverse Events | 60 months, 19 days | Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With a Partial or Complete Response | Every 6 weeks for up to a year | Percentage of participants | NUMBER | |
| SECONDARY | Number of Participants With Adverse Events | 60 months, 19 days | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Partial or Complete Response | Surgery Plus Chemotherapy | Complete Response | 4 | Percentage of participants | |
| Percentage of Participants With a Partial or Complete Response | Surgery Plus Chemotherapy | Partial Response | 6 | Percentage of participants | |
| Number of Participants With Adverse Events | Surgery Plus Chemotherapy | 49 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Surgery Plus Chemotherapy | 50 | |
| Overall Study | COMPLETED | Surgery Plus Chemotherapy | 49 | |
| Overall Study | NOT COMPLETED | Surgery Plus Chemotherapy | 1 |
Source ClinicalTrials.gov
Adverse events124
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction/hypersensitivity (including drug fever) | Immune system disorders | Surgery Plus Chemothrapy | 3 | 50 | 3 |
| other | Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip) | Immune system disorders | Surgery Plus Chemothrapy | 9 | 50 | 11 |
| other | Hemoglobin | Blood and lymphatic system disorders | Surgery Plus Chemothrapy | 47 | 50 | 176 |
| other | Leukocytes (total WBC) | Blood and lymphatic system disorders | Surgery Plus Chemothrapy | 34 | 50 | 62 |
| other | Neutrophils/granulocytes (ANC/AGC) | Blood and lymphatic system disorders | Surgery Plus Chemothrapy | 45 | 50 | 101 |
| other | Platelets | Blood and lymphatic system disorders | Surgery Plus Chemothrapy | 33 | 50 | 109 |
| other | Palpitations | Cardiac disorders | Surgery Plus Chemothrapy | 1 | 50 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Surgery Plus Chemothrapy | 1 | 50 | 1 |
| other | Vasovagal episode | Cardiac disorders | Surgery Plus Chemothrapy | 1 | 50 | 1 |
| other | Cardiac left ventricular function | Cardiac disorders | Surgery Plus Chemothrapy | 1 | 50 | 1 |
1 to 10 of 124Source ClinicalTrials.gov
See all 124 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Surgery Plus Chemothrapy | ||
| Total, other adverse events | Surgery Plus Chemothrapy | 49 | 50 |
| Total, serious adverse events | Surgery Plus Chemothrapy | 13 | 50 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 3787475 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00071058
GET https://conductscience.org/api/trials/v1/NCT00071058/events?page=2